Related Experiment Videos
Acute lymphoblastic leukaemia: diagnosis and classification
Partow Kebriaei1, John Anastasi, Richard A Larson
1Section of Hematology/Oncology, Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA.
Best Practice & Research. Clinical Haematology
|March 6, 2003
Summary
Acute lymphoblastic leukaemia (ALL) classification relies on cytogenetic analysis. Specific chromosomal abnormalities in ALL impact prognosis, guiding treatment planning for better patient outcomes.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Acute lymphoblastic leukaemia (ALL) is a complex blood cancer with varied biological features.
- Diagnosis traditionally involves cytomorphology, immunohistochemistry, and cytogenetic analysis.
- Chromosomal abnormalities are key for classifying ALL subtypes and predicting patient outcomes.
Purpose of the Study:
- To elucidate the role of chromosomal abnormalities in classifying Acute lymphoblastic leukaemia (ALL).
- To highlight the prognostic significance of specific genetic alterations in ALL.
- To emphasize the importance of cytogenetic analysis in treatment planning for ALL patients.
Main Methods:
- Cytogenetic analysis to identify numerical and structural chromosomal abnormalities.
- Evaluation of major chromosomal abnormalities including translocations and ploidy.
- Application of advanced techniques like fluorescence in situ hybridization (FISH) and DNA microarrays.
Main Results:
- Hyperdiploidy generally indicates a good prognosis, particularly in pediatric ALL.
- Hypodiploidy is associated with a poor prognosis.
- Specific abnormalities like t(9;22) (BCR/ABL) and MLL rearrangements confer poor prognosis, while t(12;21) (TEL/AML1) and del(12p) suggest a good prognosis.
Conclusions:
- Cytogenetic analysis is crucial for accurate ALL subtyping and prognostic assessment.
- Distinct chromosomal abnormalities significantly influence treatment strategies and patient outcomes in ALL.
- Emerging technologies like FISH and DNA microarrays enhance diagnostic and prognostic capabilities in ALL management.